🇺🇸 Dual antiplatelet therapy in United States

14 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Haemorrhage — 3 reports (21.43%)
  2. Multiple Organ Dysfunction Syndrome — 2 reports (14.29%)
  3. Trichophytosis — 2 reports (14.29%)
  4. Acute Pulmonary Oedema — 1 report (7.14%)
  5. Bradyarrhythmia — 1 report (7.14%)
  6. Brash Syndrome — 1 report (7.14%)
  7. Cardiac Disorder — 1 report (7.14%)
  8. Condition Aggravated — 1 report (7.14%)
  9. Dialysis — 1 report (7.14%)
  10. Dizziness — 1 report (7.14%)

Source database →

Dual antiplatelet therapy in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Dual antiplatelet therapy approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Dual antiplatelet therapy in United States?

McMaster University is the originator. The local marketing authorisation holder may differ — check the official source linked above.